S&P 500   2,628.31 (+0.06%)
DOW   22,379.18 (+0.23%)
QQQ   193.14 (+0.57%)
AAPL   258.58 (+1.48%)
FB   168.76 (+1.69%)
MSFT   160.79 (+0.35%)
GOOGL   1,168.24 (+1.91%)
AMZN   1,970.00 (+0.31%)
CGC   14.87 (+2.84%)
NVDA   268.86 (+1.23%)
BABA   194.98 (+1.94%)
MU   44.16 (-0.81%)
GE   8.00 (+1.39%)
TSLA   537.01 (+6.95%)
AMD   47.50 (-0.75%)
T   29.78 (-1.49%)
ACB   0.94 (+6.78%)
F   5.10 (+1.39%)
BAC   22.22 (+0.82%)
GILD   75.28 (-0.86%)
PRI   90.05 (-0.73%)
DIS   101.02 (+1.22%)
S&P 500   2,628.31 (+0.06%)
DOW   22,379.18 (+0.23%)
QQQ   193.14 (+0.57%)
AAPL   258.58 (+1.48%)
FB   168.76 (+1.69%)
MSFT   160.79 (+0.35%)
GOOGL   1,168.24 (+1.91%)
AMZN   1,970.00 (+0.31%)
CGC   14.87 (+2.84%)
NVDA   268.86 (+1.23%)
BABA   194.98 (+1.94%)
MU   44.16 (-0.81%)
GE   8.00 (+1.39%)
TSLA   537.01 (+6.95%)
AMD   47.50 (-0.75%)
T   29.78 (-1.49%)
ACB   0.94 (+6.78%)
F   5.10 (+1.39%)
BAC   22.22 (+0.82%)
GILD   75.28 (-0.86%)
PRI   90.05 (-0.73%)
DIS   101.02 (+1.22%)
S&P 500   2,628.31 (+0.06%)
DOW   22,379.18 (+0.23%)
QQQ   193.14 (+0.57%)
AAPL   258.58 (+1.48%)
FB   168.76 (+1.69%)
MSFT   160.79 (+0.35%)
GOOGL   1,168.24 (+1.91%)
AMZN   1,970.00 (+0.31%)
CGC   14.87 (+2.84%)
NVDA   268.86 (+1.23%)
BABA   194.98 (+1.94%)
MU   44.16 (-0.81%)
GE   8.00 (+1.39%)
TSLA   537.01 (+6.95%)
AMD   47.50 (-0.75%)
T   29.78 (-1.49%)
ACB   0.94 (+6.78%)
F   5.10 (+1.39%)
BAC   22.22 (+0.82%)
GILD   75.28 (-0.86%)
PRI   90.05 (-0.73%)
DIS   101.02 (+1.22%)
S&P 500   2,628.31 (+0.06%)
DOW   22,379.18 (+0.23%)
QQQ   193.14 (+0.57%)
AAPL   258.58 (+1.48%)
FB   168.76 (+1.69%)
MSFT   160.79 (+0.35%)
GOOGL   1,168.24 (+1.91%)
AMZN   1,970.00 (+0.31%)
CGC   14.87 (+2.84%)
NVDA   268.86 (+1.23%)
BABA   194.98 (+1.94%)
MU   44.16 (-0.81%)
GE   8.00 (+1.39%)
TSLA   537.01 (+6.95%)
AMD   47.50 (-0.75%)
T   29.78 (-1.49%)
ACB   0.94 (+6.78%)
F   5.10 (+1.39%)
BAC   22.22 (+0.82%)
GILD   75.28 (-0.86%)
PRI   90.05 (-0.73%)
DIS   101.02 (+1.22%)
Log in

NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, Forecast & News

$43.62
+2.30 (+5.57 %)
(As of 03/31/2020 12:05 PM ET)
Today's Range
$42.24
Now: $43.62
$44.49
50-Day Range
$31.65
MA: $40.62
$46.87
52-Week Range
$21.56
Now: $43.62
$53.70
Volume789,534 shs
Average Volume1.51 million shs
Market Capitalization$6.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Read More
ACADIA Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$339.08 million
Book Value$4.54 per share

Profitability

Net Income$-235,260,000.00

Miscellaneous

Employees465
Market Cap$6.78 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.


ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

How has ACADIA Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACAD shares have increased by 17.8% and is now trading at $43.43. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ACADIA Pharmaceuticals?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ACADIA Pharmaceuticals.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for ACADIA Pharmaceuticals.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.03. The biopharmaceutical company earned $98.33 million during the quarter, compared to analysts' expectations of $95.87 million. ACADIA Pharmaceuticals had a negative return on equity of 42.86% and a negative net margin of 69.38%. View ACADIA Pharmaceuticals' earnings history.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Wednesday, February, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $440-470 million, compared to the consensus revenue estimate of $444.04 million.

What price target have analysts set for ACAD?

16 brokerages have issued 1 year price targets for ACADIA Pharmaceuticals' stock. Their forecasts range from $31.00 to $75.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $55.31 in the next year. This suggests a possible upside of 27.4% from the stock's current price. View analysts' price targets for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (12/31/2019)
  • 2. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $71.86/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $3.50 discounted back to and (b) an NPV of $47.36/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Nuplazid in further clinical studies; (2) failure of Nuplazid to secure regulatory approval in further indications; and (3) failure of Nuplazid to achieve peak commercial revenue estimates in our model, due to market size, penetration rates, and pricing." (5/3/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "Dexcom posted another sizable sales beat, besting consensus expectation by almost $35M, and raised 2019 revenue guidance by $75M. The familiar topics of pricing and competition ruled much of the discussion, but there was little new on either front, in our view. Some revenue is expected to go toward higher operating expenses as the company invests in new markets, the Verily product, and G6 line extensions. We remain concerned that pricing pressures could arise—perhaps suddenly—but also may not occur for years. We frankly haven’t figured out what work to do to predict when or if insurers may push on price due to competition pricing lower. We remain Neutral as we feel we have no way to eliminate or estimate this risk but do believe DXCM shares will move higher should pricing fears not play out. CGM is good medicine and should be used by all MDI diabetics, in our view." (5/2/2019)

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

Media headlines about ACAD stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutACADIA Pharmaceuticals.

Who are some of ACADIA Pharmaceuticals' key competitors?

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Sarepta Therapeutics (SRPT), Celgene (CELG), NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Alibaba Group (BABA), Citigroup (C), Synergy Pharmaceuticals (SGYP) and Tesla (TSLA).

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:
  • Mr. Stephen R. Davis, CEO & Director (Age 58)
  • Dr. Srdjan R. Stankovic, Pres (Age 62)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)
  • Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 39)
  • Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40)

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $43.43.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $6.75 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe. View additional information about ACADIA Pharmaceuticals.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is http://www.acadia-pharm.com/.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  746 (Vote Outperform)
Underperform Votes:  407 (Vote Underperform)
Total Votes:  1,153
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel